COMBINATION THERAPY OF IMIPRAMINE AND QUETIAPINE IN AMELIORATION OF COMORBID DEPRESSION AND ANXIETY DISORDERS
Bulletin of Pharmaceutical Research · 2026-08 · 16 (2)
DOI: 10.21276/bpr.2026.16.2.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Pharmaceutical Research, 2026-08. Verfasst von Joyeeta T Khan und 3 weiteren Autor:innen.
Themen: Depression
Abstract (Originalsprache)
Depression and anxiety are considered one of the most prevalent, costly, and burdensome mental health disorders worldwide, with a significant impact on patient’s individual and societal wellbeing. Antidepressants with mood-stabilizing agents are frequently employed in treatment of these debilitating conditions. Besides, treatments of schizophrenia and other complex mental health conditions often possess sedative effects, which induce comorbid or secondary depression, anxiety disorders. Such situations can be challenging due to complexity of the conditions, requiring a combination of psychopharmacological medication to address multiple diseases. Quetiapine is a widely utilized antipsychotic medication, particularly effective in the management of schizophrenia whilst Imipramine is a potent depression inhibitor. The combination of Quetiapine and Imipramine was chosen for this experiment to evaluate the synergy, compatibility, pharmacological advantages, toxicity mitigation and augmentation of effectiveness in patients suffering with secondary depressive symptoms. Mice were fed Quetiapine, Imipramine alone and combination of these drugs separately in groups. Afterwards, Tail Suspension Test (TST) and Forced Swim Test (FST) were conducted on Swiss Albino mice to trigger depression like symptoms followed by behavioral analysis of them. The study revealed that both 0.30 mg Quetiapine and 0.07 mg Imipramine combination as well as 0.60 mg Quetiapine and 0.14 mg Imipramine combination have potential anti-depressant effects. The combination of drugs may be beneficial for comorbid depression and associated mental health disorders. The mood stabilizing characteristics of Imipramine may also be effective in alleviating Quetiapine-induced toxicity. Nevertheless, further extensive research is warranted to confirm the findings, determine the mechanistic pathways involved, optimal dosage and duration of the combination treatment.
Zitieren
APA
Khan, J. T., Naim, S. M. R. Q., Nawrin, K., & Chandrabose, K. (2026). COMBINATION THERAPY OF IMIPRAMINE AND QUETIAPINE IN AMELIORATION OF COMORBID DEPRESSION AND ANXIETY DISORDERS. Bulletin of Pharmaceutical Research, 16(2). https://doi.org/10.21276/bpr.2026.16.2.4
Vancouver
Khan JT, Naim SMRQ, Nawrin K, Chandrabose K. COMBINATION THERAPY OF IMIPRAMINE AND QUETIAPINE IN AMELIORATION OF COMORBID DEPRESSION AND ANXIETY DISORDERS. Bulletin of Pharmaceutical Research. 2026;16(2). doi:10.21276/bpr.2026.16.2.4
BibTeX
@article{Khan2026,
author = {Khan, Joyeeta T and Naim, S M Ruhul Qudus and Nawrin, Kashfia and Chandrabose, Karthikeyan},
title = {COMBINATION THERAPY OF IMIPRAMINE AND QUETIAPINE IN AMELIORATION OF COMORBID DEPRESSION AND ANXIETY DISORDERS},
journal = {Bulletin of Pharmaceutical Research},
year = {2026},
volume = {16},
number = {2},
doi = {10.21276/bpr.2026.16.2.4}
}
EUVIMED